middle.news
Chimeric Therapeutics Secures $1.62M Advance to Fuel Phase 1/2 Trials
2:10pm on Wednesday 29th of July, 2026 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Secures $1.62M Advance to Fuel Phase 1/2 Trials
2:10pm on Wednesday 29th of July, 2026 AEST
Key Points
Received $1.62 million advance from Endpoints Capital
Funding secured against anticipated FY26 R&D tax incentive
Supports Phase 1/2 clinical trials and working capital
Previous R&D facility with Radium Capital fully repaid
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE